MedTrace Logo

Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants

NCT01545245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 343

Last updated 2014-12-08

No results posted yet for this study

Summary

The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for respiratory syncytial (RS) virus infections during the infancy.

The secondary objective is to determine whether the incidence of recurrent wheezing after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy.

Conditions

  • Atopic Asthma
  • Recurrent Wheezing

Sponsors & Collaborators

  • Scientific Committee for Elucidation of Infantile Asthma

    collaborator UNKNOWN

  • Tokai University

    lead OTHER

Principal Investigators

  • Hiroyuki Mochizuki, M.D., Ph.D., · Professor, Department of Pediatrics, Tokai University School of Medicine

Eligibility

Min Age
3 Years
Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-01-31
Completion
2014-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01545245 on ClinicalTrials.gov